JGC
FBRX icon

J. Goldman & Co’s Forte Biosciences FBRX Stock Holding History

J. Goldman & Co’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
54,174
-6,626
-11% -$191K 0.04% 377
2025
Q4 		$1.66M Buy
+60,800
New +$1.07M 0.04% 340
2021
Q3 		– Sell
-266
Closed -$224K – 379
2021
Q2 		$224K Sell
266
-809
-75% -$729K 0.01% 352
2021
Q1 		$921K Buy
1,075
+308
+40% +$252K 0.03% 313
2020
Q4 		$698K Buy
+767
New +$721K 0.04% 261
2019
Q2 		– Sell
-173
Closed -$513K – 293
2019
Q1 		$707K Buy
+173
New +$668K 0.04% 216

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

J. Goldman & Co's FBRX Position: Q1 2026 in Review

J. Goldman & Co reduced its Forte Biosciences (FBRX) stake by 11% in Q1 2026, selling an estimated $191K and leaving 54,174 shares worth $1.4M. The position accounts for 0.04% of the portfolio, ranked #377.

J. Goldman & Co first reported a position in FBRX in Q1 2019 and has held it in 6 quarters since. The position peaked at $1.66M in Q4 2025. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • J. Goldman & Co held 54,174 shares of Forte Biosciences worth $1.4M as of Q1 2026.
  • J. Goldman & Co sold 6,626 Forte Biosciences shares in Q1 2026, an estimated $191K.
  • Forte Biosciences made up 0.04% of J. Goldman & Co's portfolio in Q1 2026, its #377 holding.
  • J. Goldman & Co first reported a position in Forte Biosciences in Q1 2019 and has held it in 6 quarters since.
  • J. Goldman & Co's Forte Biosciences position peaked at $1.66M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.